Jeevan Scientific Technology Quarterly Results for Trading Insights
In Sept 2025, Jeevan Scientific Technology (JSTL) reported revenue ₹13 Cr and net profit ₹0 Cr — revenue +8.3% YoY. For annual financials, live price and key ratios, visit JSTL stock price BSE.
JSTL Quarterly Results — Revenue, Profit & EPS Highlights
Jeevan Scientific Technology latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Compare with JSTL stock valuation models to assess whether the stock is under or overvalued.
- Revenue of ₹13 Cr in Sept 2025 (+30.0% vs Mar 2025, +8.3% vs Sept 2024)
- EBITDA of ₹2 Cr in Sept 2025
- Operating Margin of 17.0% in Sept 2025 (+21.0pp vs Mar 2025)
- Earnings Per Share of ₹0.01 in Sept 2025 (+101.2% vs Mar 2025)
Jeevan Scientific Technology Quarterly Results — Revenue, EBITDA, Net Profit & EPS
JSTL quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Sept 2024 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 13 | 10 | 9 | 19 | 12 | 30.0% | 8.3% |
| Net Profit (₹ Cr) | 0 | -1 | -3 | 2 | 0 | - | - |
| EBITDA (₹ Cr) | 2 | 0 | -1 | 5 | 3 | - | - |
| EPS (₹) | 0.01 | -0.81 | -2.03 | 1.52 | 0.16 | - | - |
| Operating Margin (%) | 17.0% | -4.0% | -20.0% | 27.0% | 22.0% | - | - |
JSTL Share Price Trend — 1-Year Movement Across Quarterly Results
Jeevan Scientific Technology 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Analyse JSTL shareholding pattern to track promoter, FII and institutional holdings.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
JSTL vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Jeevan Scientific Technology latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Sept 2025 |
₹396,418.12 Cr | 1652.2 | 14,875 | 3,125 | +10.8% | - | 21.0% | 127.1 |
|
Divis Laboratories
Sept 2025 |
₹162,373.86 Cr | 6070.0 | 2,860 | 689 | +7.1% | - | 24.1% | 233.7 |
|
Torrent Pharmaceuti…
Sept 2025 |
₹140,630.85 Cr | 4181.0 | 3,219 | 591 | +11.3% | - | 18.4% | 238.4 |
|
Lupin
Sept 2025 |
₹106,664.75 Cr | 2315.1 | 6,921 | 1,485 | +23.2% | - | 21.5% | 71.5 |
|
Dr Reddys Laborator…
Sept 2025 |
₹102,844.71 Cr | 1235.9 | 9,135 | 1,337 | +1.1% | - | 14.6% | 76.4 |
All amounts in ₹ Crores